Host genomics of the HIV-1 reservoir size and its decay rate during

2 suppressive antiretroviral treatment

- 4 Christian W. Thorball^{1,*}, Alessandro Borghesi^{1,2,*}, Nadine Bachmann^{3,4}, Chantal von
- 5 Siebenthal^{3,4}, Valentina Vongrad^{3,4}, Teja Turk^{3,4}, Kathrin Neumann^{3,4}, Niko Beerenwinkel^{5,6},
- 6 Jasmina Bogojeska⁷, Volker Roth⁸, Yik Lim Kok^{3,4}, Sonali Parbhoo^{8,9}, Mario Wieser⁸, Jürg
- 7 Böni⁴, Matthieu Perreau¹⁰, Thomas Klimkait¹¹, Sabine Yerly¹², Manuel Battegay¹³, Andri
- 8 Rauch¹⁴, Patrick Schmid¹⁵, Enos Bernasconi¹⁶, Matthias Cavassini¹⁷, Roger D. Kouyos^{3,4},
- 9 Huldrych F. Günthard^{3,4}, Karin J. Metzner^{3,4}, Jacques Fellay^{1,18,§} and the Swiss HIV Cohort
- 10 Study

11

1

3

- 12 1 School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- 13 2 Neonatal Intensive Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- 14 3 Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich,
- 15 Zurich, Switzerland.
- 16 4 Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
- 5 Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
- 18 6 SIB Swiss Institute of Bioinformatics, Basel, Switzerland.
- 19 7 IBM Research Zurich, Rüschlikon, Switzerland.
- 20 8 Department of Mathematics and Computer Science, University of Basel, Basel, Switzerland.
- 9 Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University,
- 22 Cambridge, MA, USA.
- 23 10 Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, University
- of Lausanne, Lausanne, Switzerland.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 25 11 Division Infection Diagnostics, Department Biomedicine—Petersplatz, University of Basel,
- 26 Basel, Switzerland.
- 27 12 Division of Infectious Diseases and Laboratory of Virology, University Hospital Geneva,
- 28 University of Geneva, Geneva, Switzerland.
- 29 13 Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel,
- 30 Basel, Switzerland.
- 31 14 Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland.
- 32 15 Division of Infectious Diseases, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland.
- 33 16 Infectious Diseases Service, Regional Hospital of Lugano, Lugano, Switzerland.
- 34 17 Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, University of
- 35 Lausanne, Lausanne, Switzerland.
- 36 18 Precision Medicine Unit, Lausanne University Hospital (CHUV) and University of
- 37 Lausanne, Lausanne, Switzerland
- 38 * Equal contribution
- 40 § Corresponding author:
- 41 Jacques Fellay

47

48

- 42 School of Life Sciences
- 43 École Polytechnique Fédérale de Lausanne
- 44 1015 Lausanne, Switzerland
- 45 E-mail: jacques.fellay@epfl.ch
- 46 Phone number: +41216931849
- 49 **Keywords**: HIV, genetics, ART, latent reservoir, GWAS, exome sequencing

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

ABSTRACT

Introduction A major hurdle to HIV-1 eradication is the establishment of a latent viral reservoir early after primary infection. Several factors are known to influence the HIV-1 reservoir size and decay rate on suppressive antiretroviral treatment (ART), but little is known about the role of human genetic variation. Methods We measured the reservoir size at three time points over a median of 5.4 years, and searched for associations between human genetic variation and two phenotypic readouts: the reservoir size at the first time point and its decay rate over the study period. We assessed the contribution of common genetic variants using genome-wide genotyping data from 797 patients with European ancestry enrolled in the Swiss HIV Cohort Study and searched for a potential impact of rare variants and exonic copy number variants using exome sequencing data generated in a subset of 194 study participants. **Results** Genome- and exome-wide analyses did not reveal any significant association with the size of the HIV-1 reservoir or its decay rate on suppressive ART. **Conclusions** Our results point to a limited influence of human genetics on the size of the HIV-1 reservoir and its long-term dynamics in successfully treated individuals.

INTRODUCTION

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

Combination antiretroviral treatment (ART) has turned the previously lethal infection by human immunodeficiency virus type 1 (HIV-1) into a chronic disease. Despite this significant achievement, HIV-1 as retrovirus, self-integrating its genome into the host chromosome, persists indefinitely in infected individuals during treatment [1–4], and life-long ART is required to control the infection. A major hurdle to HIV-1 eradication is the establishment, already during primary infection, of a latent viral reservoir of HIV-1 DNA persisting as provirus in resting memory CD4⁺ T cells [1,2,5–8]. At the molecular level, chromatin remodeling, epigenetic modifications, transcriptional interference, and availability of transcription factors have been considered as possible mechanisms contributing to HIV-1 latency [9]. The viral reservoir is measurable through different methods, including viral outgrowth assay and intracellular HIV-1 DNA quantification [10,11]. Currently, there is no consensus on the best HIV-1 reservoir biomarker. Total cell-associated HIV-1 DNA, easy to measure in different cell and tissue samples and applicable to large populations, has been shown to be a good proxy for the reservoir size [12]. Indeed, while HIV-1 DNA measurement is able to detect both integrated and nonintegrated viral genomes coding for intact or defective viruses [13], total HIV-1 DNA levels have been shown to correlate with viral outgrowth [14], and to predict the time to viral rebound at treatment interruption [15]. Moreover, the substantial loss of nonintegrated HIV-1 DNA genomes following ART initiation suggests that total HIV-1 DNA after prolonged suppression is largely accounted for by integrated viral genomes [16]. After an initial rapid decay following ART initiation, changes of the viral reservoir size over time display wide inter-individual variability. By limiting dilution culture assay, the half-life of the viral reservoir was first estimated to be 44 months (95% confidence interval 27.4-114.5) in individuals with undetectable viremia [4]. A more recent study showed a slow decline of total

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

HIV-1 DNA with a half-life of 13 years after the first four years of suppressive ART [17]. Generally, different studies show a broad variability of the average decay rate, from 2.5 months to no measurable decay [18–26]. One study even reported an increase in the viral reservoir size in as much as 31% of patients in the 4-7 years following ART initiation [27], and recent data from our group confirm this observation, reporting an increase in the reservoir size in 26.8% of individuals in the 1.5-5.5 years after ART initiation [28]. Several factors are known to influence the decay rate of the viral reservoir: initiation of ART during acute HIV-1 infection substantially accelerates the decay rate, while viral blips and lowlevel viremia during ART slow it down, as shown in previous studies [22] and in recent data from our cohort [28]. Conversely, treatment intensification, i.e. treating with additional drugs, does not appear to influence the decay rate, suggesting that residual replication is not the main driver of the viral reservoir [29] or that it may happen in sanctuary sites. Human genetic variants have been shown to influence the outcome of various infections, including HIV. Previous genome-wide association studies (GWAS) addressed the role of common genetic polymorphisms in several HIV-related phenotypes, including plasma viral load (HIV-1 RNA) at set point, exceptional capacity to control viral replication, pace of CD4+ T lymphocyte decline, time to clinical AIDS, rapid progressor status or long-term nonprogressor status (LTNP) [30–37], and, in one single study, the amount of intracellular HIV-1 DNA, measured at a single time point during the chronic phase of infection [38]. Rare genetic variants that are detectable through DNA sequencing technologies have been investigated far less. However, a large exome sequencing study did not reveal any convincing association of such variants with the natural history of HIV disease [39]. To date, no studies have addressed the role of human genetic variation in determining the initial viral reservoir size and the reservoir decay rate over time. In the current study, we searched for

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

host genetic factors associated with the HIV-1 reservoir size and its long-term dynamics in a cohort of 797 HIV-1 positive individuals on suppressive ART for at least five years. **METHODS Ethics statement** Participants in the Swiss HIV Cohort Study (SHCS) consented to the cohort study and genetic analyses, as approved by the corresponding local Ethics Committees. **Study participants** The SHCS is an ongoing, nation-wide cohort study of HIV-positive individuals, including more than 70% of all persons living with HIV in Switzerland. Clinical and laboratory information has been prospectively recorded at follow-up visits every 3-6 months since 1988 [40]. The general enrolment criteria have been described previously [28]. Additionally, availability of genome-wide genotyping data from previous studies or of a DNA sample for genotyping was required for inclusion in this study (Figure 1). Quantification of total HIV-1 DNA The collection of longitudinal cryopreserved peripheral blood mononuclear cells (PBMCs) from eligible participants and the quantification of total HIV-1 DNA by droplet digital PCR has been described previously along with the calculation of the reservoir decay rate [28]. Briefly, this study utilized total HIV-1 DNA quantifications from three time points at a median of ~1.5 years, \sim 3.5 years, and \sim 5.4 years after initiation of ART. Genotyping and genome-wide association analyses

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

Genome-wide genotyping data were obtained from previous GWAS that used various microarrays, including the HumanCore-12, HumanHap550, Human610, Human1M and Infinium CoreExome-24 BeadChips (Illumina Inc., San Diego, CA, USA), or generated from DNA extracted from peripheral blood mononuclear cells using the HumanOmniExpress-24 BeadChip (Illumina Inc., San Diego, CA, USA). Genotypes from each genotyping array were filtered and imputed separately, with variants first flipped to the correct strand with BCFTOOLS (v1.8) according to the human GRCh37 reference genome and filtered based on a less than 20% deviation from the 1000 genomes phase 3 EUR reference panel. Genotypes were phased, and missing genotypes were imputed with EAGLE2 [41] and PBWT [42] respectively, using the 1000 Genomes Project Phase 3 reference panel on the Sanger Imputation Service [43]. Study participants were filtered based on European ancestry as determined by principal component analysis (PCA) using EIGENSTRAT (v6.1.4) [44] and the HapMap project [45] as reference populations (Figure S1A). Imputed variants were filtered by minor allele frequency (MAF) < 5%, missingness > 10%, deviation from Hardy-Weinberg equilibrium ($P_{HWE} < 1e-6$) and imputation quality score (INFO < 0.8). The remaining genotypes were then combined using PLINK (v1.90b5) [46] prior to analyses. To carry out the GWASs, genome-wide genotypes were tested for association with each of the two study phenotypes (reservoir size or reservoir decay rate) in two separate genome-wide association analyses. Statistical significance was set to the standard genome-wide significance threshold of P < 5e-8 to correct for multiple testing. The associations were computed using linear mixed models with genetic relationship matrixes calculated between pairs of individuals according to the leave-one-chromosome-out method as implemented in GCTA mlma-loco (v1.91.4beta) [47,48], only including age and sex as covariates, to avoid masking of true associations by confounders. To further assess the contribution of variables previously shown to be associated with either reservoir size or decay rate, we ran multiple genome-wide

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

association analyses, each including age, sex, and one single covariate, for each of the two study phenotypes. Finally, we conducted a GWAS including all the covariates except those showing mutual correlations. These covariates included time on ART, time to viral suppression, infection stage (acute or chronic), HIV-1 RNA pre-ART, last CD4+ T cell count pre-ART, HIV-1 subtype, transmission group, and occurrence of blips or low-level viremia during treatment. Classical HLA alleles at the four-digit level and variable amino acids within HLA proteins were imputed using SNP2HLA (v1.03) with the T1DGC reference panel consisting of 5,225 individuals of European ancestry [49]. Association analyses with the imputed HLA alleles and multi-allelic amino acids was performed using linear regressions in PLINK and multivariate omnibus tests, respectively. For all HLA analyses age, sex and the first principal component was included as covariates. Genotypes at specific loci, i.e. the CCR5Δ32 deletion (rs333) and the HLA-B*57:01 allele, known to influence the setpoint viral load (spVL) [50,51], available from genome-wide genotyping data, were tested for association with the reservoir size and its decay rate in 797 patients. High quality genotyping information on the CCR5Δ32 deletion was available for most individuals (N = 687), while all had available HLA information. Exome sequencing and analysis All coding exons were captured using either the Illumina Truseq 65 Mb enrichment kit (Illumina Inc., San Diego, CA, USA) or the IDT xGen Exome Research Panel v1.0 (Integrated DNA Technologies Inc., Coralville, IA, USA) and sequenced on the Illumina HiSeq4000. Sequence reads were aligned to the human reference genome (GRCh37) including decoys with BWA-MEM (v0.7.10) [52]. PCR duplicates were flagged using Picard tools (v2.18.14) and variant calling performed using GATK (v3.7) [53].

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

To ensure a high-quality variant set across capture kit batches, all samples were merged and variants filtered based on sequencing depth (DP \geq 20) and genotype quality (GQ \geq 30) using BCFTOOLS (v1.8). Furthermore, individual genotypes were set as missing in cases of low depth (DP < 10) or low quality (GQ < 20). The effect of the included variants was annotated with SnpEff (v4.3T) [54]. For single variant association analysis, the VCF file was converted to PLINK format using BCFTOOLS and PLINK. Only variants with a MAF above 5%, missingness per variant below 5% and absence of severe deviation from Hardy-Weinberg equilibrium (P_{HWE} > 1e-6) were retained for the subsequent association analyses using PLINK. Sex, age and the first principal component were included as covariates. Only individuals of European descent were retained for the analyses, as determined by PCA (Figure S1B). The combined effect of rare protein-altering variants (MAF < 5%), defined as either missense, stop-gain, frameshift, essential splice variant or an indel by SnpEff, on the reservoir size and decay rate was analyzed using optimal sequence kernel association tests (SKAT-O) [55]. For the decay rate, individuals were split into two groups due to the non-normal distribution; one exhibiting a very high decay over time (< -0.03 -log10(DNA)) and another with a stable reservoir size (\geq -0.03 and \leq 0.03 -log10(DNA)). For this case-control analysis we used the SKATbinary function with linear weighted variants as implemented in the SKAT R package. In both cases, the analyses were adjusted for age, sex, and the first principal component. Classical HLA class I and II alleles at the four-digit level were imputed from the exome sequencing data using HLA*LA [56]. All reads mapping to the MHC region or marked as unmapped were extracted using Samtools (v1.8) and used as input into HLA*LA. For association analyses, the 4-digit HLA alleles were extracted and analyzed using PyHLA [57] assuming an additive model, a minimum frequency of 5% and including age, sex and the first principal component as covariates.

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

Copy number variation Copy number variations (CNVs) were called from exome sequencing data using CLAMMS [58]. CNVs were called for all samples in batches according to the exome capture kit used. Within batches, samples were normalized based on coverage and potential intra-batch effects adjusted for through the use of recommended mapping metrics extracted with Picard tools (v2.18.14). After CNV calling, samples with the number of CNVs two times above the median were excluded (N = 2). CNV association analyses were performed for duplications and deletions separately for common CNVs (frequency > 5 %) with PLINK adjusting for age and sex. Potential rare CNVs (frequency < 5%) impacting immune related genes were examined by overlapping called CNVs with curated immune-related genes from Immport [59] which were also listed as protein coding in GENCODE (v25). Statistical analyses All statistical analyses were performed using the R statistical software (v3.5.2), unless otherwise specified. **RESULTS** Host genetic determinants of the reservoir size and long-term dynamics To investigate the effects of host genetic variation on the size of the HIV-1 reservoir 1.5 years after ART initiation and its long-term dynamics under ART over a median duration of 5.4 years, we performed a GWAS, including 797 well-characterized HIV-1 positive individuals. All study participants were enrolled in the SHCS and were of European ancestry with longitudinal total HIV-1 DNA measurements available (Table 1). The median HIV-1 reservoir size was 2.76 (IQR: 2.48-3.03) log10 total HIV-1 DNA copies/1 million genomic equivalents measured ~1.5 years after initiation of ART (Figure S2A). The median decay rate between 1.5-5.4 years after initiation of ART was -0.06 (IQR: -0.12-0.00) log10 total HIV-1 DNA copies/1 million genomic equivalents per year (Figure S2B). With our sample size we had 80% power to detect variants with a MAF of 10% explaining at least 5% of the variance in HIV-1 reservoir size or decay rate [60]. First, we performed GWAS using age and sex as covariates. We did not observe any genomewide significant variant (P < 5e-8) associated with either HIV-1 reservoir size or long-term dynamics (Figure 2, S3). However, as we have previously determined, multiple factors are associated with the HIV-1 reservoir size and its decay rate [28], some of which are correlated (Figure S4). Thus, we performed additional analyses iteratively including these factors to test whether they could mask genetic associations. We ran multiple GWAS each adjusting for age, sex, plus one of the associated covariates, as well as all of the covariates together. The addition of the covariates did not have any significant effect on the results nor the genome-wide inflation factor (lambda) (Table S1). Genetic variation in the HLA region has previously been associated with multiple HIV-related outcomes, including spVL [51]. To test whether specific HLA variants were associated with reservoir size or long-term dynamics, we imputed the HLA alleles and amino acids for all 797 individuals from the genotyping data. In line with the previous results, we did not observe any genome-wide significant associations with any HLA allele or amino acid.

Impact of protein-coding and rare variants

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

To assess the impact of rare variants as well as protein-coding variants missed by genotyping arrays on the HIV-1 reservoir size and long-term dynamics, we performed exome sequencing in 194 of the 797 study participants. Patients were selected at the two extremes of the observed

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

reservoir decay rate: either very rapid, or absent (no change in reservoir size over ~5.4 years), while individuals with increasing HIV-1 reservoir sizes were excluded (N=12). Thus, the longterm dynamics phenotype was binarized for subsequent analyses of the decay rate, while the HIV-1 reservoir size phenotype remained normally distributed (Figure S5). To ensure that no common variants, missed by the genotype chips, were associated with the HIV-1 reservoir size or long-term dynamics, we performed a GWAS for common variants using age and sex as covariates. As with the genotyping data, we observed no genome-wide significant variants for either phenotype (Figure S6). We then examined the potential role of rare variants (MAF < 5%) with a functional impact defined as either missense, frameshift, stop gained, splice acceptor or donor. Since HIV-1 primarily infects CD4+ T cells, we only included variants within genes expressed in these cells as determined by Gutierrez-Arcelus et al. [61]. The significance threshold after correcting for the number of tests performed was P = 1.21e-5. We did not observe any significant associations for either the HIV-1 reservoir or the decay rate. The AMBRA1 gene showed the strongest association with HIV-1 reservoir size (P = 4.15e-5, not significant) (Figure S7). To confirm the lack of HLA association seen with the genotyping data, we imputed the HLA haplotypes from the exome data using HLA*LA. Again, we did not observe any significant HLA association with the study outcomes. **Copy number variations** To examine the role of large exonic CNVs not captured by standard genotyping and exome pipelines, we called CNVs from the mapped sequencing reads of the exome samples using the software CLAMMS. The contribution of common CNVs to HIV-1 reservoir size and long-term dynamics was analyzed by association analyses including age, sex and the first principal component as covariates. No significant association was observed after Bonferroni correction (Figure S8). We also searched for rare CNVs in curated immune-related genes from Immport

[59] but did not discover any suggestive immune-related CNVs.

Influence of HLA-B*57:01 and the CCR5Δ32 deletion on reservoir size and long-term

dynamics

We have previously shown that pre-ART RNA viral load levels are associated with the HIV-1

reservoir size and the occurrence of blips [28]. The HLA-B*57:01 allele and the CCR5Δ32

deletion are well known genetic variants influencing HIV-1 spVL [50,51], and could thus also

be associated with the with the HIV-1 reservoir size or its decay rate. However, we did not

observe any nominal association (all P > 0.05) with either reservoir size or its long-term

dynamics for HLA-B*57:01 and CCR5Δ32 (Figure S9).

DISCUSSION

We used a combination of genomic technologies to assess the potential role of human genetic factors in determining both the HIV-1 reservoir size and its long-term dynamics in a well-characterized, population-based cohort. We studied 797 HIV-1 infected individuals of European origin under suppressive ART over a median of 5.4 years, for whom extensive clinical data are available, allowing detailed characterization and correction for potential confounders [28]. We measured the HIV-1 reservoir size at three time points and selected two phenotypes for our genomic study: the reservoir size at ~1.5 years after ART initiation and the slope of the reservoir decay rate calculated over the three time points. Previous HIV host genetic studies mostly focused on phenotypes reflecting the natural history of HIV-1 infection, prior to ART initiation, including spontaneous viral control and disease progression [30–37]. A single study specifically tested for associations between common genetic variants and the amount of

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

intracellular HIV-1 DNA, measured at a single time point during the chronic phase of infection prior to initiation of any antiretroviral therapy [38]. Here, in contrast, we longitudinally assessed samples collected from patients under suppressive ART to search for human genetic determinants of the long-term dynamics of the HIV-1 reservoir during treatment. We first conducted a GWAS on 797 individuals to test for association between common genetic variants and the phenotypes. Given the small proportion of non-European subjects in the initial study cohort, we only included patients of European ancestry to avoid any false positive associations or masking of true positive associations due to different allele frequencies in small proportions of individuals belonging to different subpopulations (Figure 1) [62]. Regardless of including or not independent covariates other than the standard ones (i.e., sex and age), no genetic variant reached the genome-wide significance threshold for association with any of the two phenotypes. This may reflect a small effect size of genetic variants on the HIV-1 reservoir size and decay rate. We acknowledge that a larger sample size and thus increased statistical power may allow detecting genetic variants with a smaller effect size associated with the phenotypes. However, it should be noted that this study is by far the largest today that has investigated the size and decay of the HIV-reservoir in well characterized and well suppressed HIV-infected individuals over a longer time period. Alternatively, the control of the HIV-1 reservoir size and its long-term dynamics may be under the control of viral or host factors other than the individual genetic background. A previous report from our group had shown a correlation between viral blips during the first 1.5 years of suppressive ART and the HIV-1 reservoir size 1.5 years after ART initiation, and between viral blips after 1.5-5.4 years of suppressive ART or low-level viremia and a slower decay rate [28]. Importantly, viral blips are generally thought to reflect transient increases in viral replication, probably occur under multifactorial influence from viral and host factors [63–70], with these latter possibly including, but not being limited to, germline genetic variation. The biological relations between viral

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

reservoir, decay rate, viral blips, and the contribution of the individual genetic background still need full elucidation. Standard GWAS is designed to detect associations with common genetic variants (i.e., with a MAF of at least 0.05), with little power to investigate the role of rare variants. Thus, to further assess the contribution of rare variants in individuals at the extreme of the decay rate distribution, we used exome sequencing in a selected subset of 194 study participants with very high decay rate, or conversely, a stable reservoir size over time (Figure S5). Here again, our analyses did not detect significant association with the phenotypes. Although not reaching statistical significance, a rare genetic variant with potential functional impact in AMBRA1 had a p-value for association just below the corrected threshold. The expression of AMBRA1, a core component of the autophagy machinery, has previously been associated with long-term viral control in HIV-1 non-progressors [71]. Future studies may further elucidate whether genetic variation in AMBRA1 may account for inter-individual differences in the long-term dynamics of the HIV-1 reservoir. Large deletions or duplications of genomic material may be implicated in human phenotypes, with CNVs impacting the exonic regions being more likely to have a functional role. Thus, we further investigated whether any common or rare CNV spanning exonic regions was associated with the phenotype. Again, no CNV was statistically associated with the phenotypes both in the exome-wide analyses and in analyses focused on immune-related genes. An inherent limitation of our exome-based association analyses was their inability to detect rare variants outside the coding or splice-site regions. The exonic regions account for approximately 1-2% of the whole human genome. Because many regulatory sequences are located in extragenic sites, our analysis did not fully investigate the role of highly conserved, non-coding genetic regions in influencing the phenotypes linked to HIV-1 latency.

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

Additionally, we focused on specific genetic variants, i.e., the HLA haplotypes and the CCR5Δ32 deletion, previously demonstrated to have a role in HIV-1 related phenotypes [30,51]. Indeed, previous studies unraveled a robust association between variation in the HLA region and the HIV-1 spVL [30]. Likewise, heterozygosity for the CCR5Δ32 deletion has been shown to influence spontaneous HIV-1 control [51]. Thus, we imputed HLA genotypes from genotyping and exome data, and studied the CCR5 Δ 32 deletion, without, however, detecting any significant associations with the phenotypes or the covariates (Figure S9). Specifically, we found no correlation between HLA genotypes and HIV-1 RNA plasma levels prior to ART initiation, apparently contrasting with the previous findings of an association between HLA-B*57:01 haplotype and spVL. This probably reflects historical changes in the therapeutic approach following a diagnosis of HIV-1 infection, given that ART is currently initiated soon after clinical diagnosis, before most patients reach a stable plateau of plasma viral load. In our study, the quantification of the reservoir size at different time points may have been influenced by factors as, for example, blips and low-level viremia, which may have reduced our ability to detect significant genetic effects. It is also possible that, in the future, novel methods to assess the viral reservoir will allow the detection of significant contributions of genetic factors [72]. So far, it remains unanswered whether the initial response to acute infection, the containment of ongoing replication, and the control of latently infected cells are under the influence of the same or different molecular networks. It needs to be noted that in previous work we have shown that host genetic factors as defined by GWAS did not explain the severity of symptoms during acute HIV-infection, although severity of symptoms correlated well with viral load and CD4 cell counts [73]. In contrast to host genetic factors, we recently identified a significant impact of the viral genome on the size of the latent reservoir 1.5 years after treatment initiation. However, what parts of the virus genome were responsible for this "viral effect" needs to be determined further.

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

Author contributions

In conclusion, our study suggests that human individual germline genetic variation has little, if any, influence on the control of the HIV-1 viral reservoir size and its long-term dynamics. Complex, likely multifactorial biological processes govern HIV-1 viral persistence. Larger studies will possibly clarify the role of common or rare genetic variants explaining small proportions of the variability of the phenotypes related to viral latency. Data availability The datasets generated during and/or analyzed during the current study are not publicly available due to privacy reasons, the sensitivities associated with HIV infections, and the representativeness of the dataset, but is available on request. **Conflicts of interest statement** H.F.G. has received unrestricted research grants from Gilead Sciences and Roche; fees for data and safety monitoring board membership from Merck; consulting/advisory board membership fees from Gilead Sciences, ViiV, Merck, Sandoz and Mepha. T.K. has received consulting/advisory board membership fees from Gilead Sciences and from ViiV Healthcare for work that has no connection to the work presented here. K.J.M. has received travel grants and honoraria from Gilead Sciences, Roche Diagnostics, GlaxoSmithKline, Merck Sharp & Dohme, Bristol-Myers Squibb, ViiV and Abbott; and the University of Zurich received research grants from Gilead Science, Roche, and Merck Sharp & Dohme for studies that Dr. Metzner serves as principal investigator, and advisory board honoraria from Gilead Sciences. All other authors declare no competing financial interests.

N.B., J.B., V.R., R.D.K., H.F.G., K.J.M., and J.F. contributed to the conception and design of 422 423 the study. C.v.S., V.V., K.N., Y.I.K., and K.J.M. contributed to the acquisition of data. A.B., C.W.T., N.B., T.T., S.P., M.W., R.D.K., and J.F. contributed to the analysis and interpretation 424 425 of data. J.B., M.P., T.K., S.Y., M.B., A.R., P.S., E.B., M.C., H.F.G., and the members of the 426 Swiss HIV Cohort Study (SHCS) conceived and managed the cohort, collected and contributed 427 patient samples and clinical data. A.B., C.W.T., and J.F. contributed to the drafting the article. 428 All authors read and approved the final manuscript. 429 430 Acknowledgements 431 We thank the patients for participating in the SHCS, the study nurses and physicians for 432 excellent patient care, A. Scherrer, A. Traytel, and S. Wild for excellent data management and 433 D. Perraudin and M. Amstutz for administrative assistance. 434 This work was funded within the framework of the Swiss HIV Cohort Study (SNF grant# 435 436 33CS30 177499 to H.F.G.). The data were gathered by the Five Swiss University Hospitals, 437 two Cantonal Hospitals, 15 affiliated hospitals and 36 private physicians (listed in 438 http://www.shcs.ch/180-health-care-providers). The work was furthermore supported by the 439 Systems.X grant # 51MRP0 158328 (to N.B., J.B., J.F., V.R., R.D.K., M.W., H.F.G. and K.J.M.), by SNF grant 324730B 179571 (to H.F.G.), SNF grant SNF 310030 141067/1 (to 440 H.F.G. and K.J.M.), SNF grants no. PZ00P3-142411 and BSSGI0 155851 to R.D.K., the 441 442 Yvonne-Jacob Foundation (to H.F.G.), the University of Zurich's Clinical Research Priority 443 Program viral infectious disease, ZPHI (to H.F.G) and the Vontobel Foundation (to H.F.G. and 444 K.J.M.). M.W. is partially supported by the NCCR MARVEL, funded by the Swiss National 445 Science Foundation.

446

- 447 Members of the Swiss HIV Cohort Study:
- 448 Anagnostopoulos A, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A,
- Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA,
- 450 Günthard HF (President of the SHCS), Haerry D (deputy of "Positive Council"), Hasse B,
- 451 Hirsch HH, Hoffmann M, Hösli I, Huber M, Kahlert CR (Chairman of the Mother & Child
- Substudy), Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti
- G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nicca D, Paioni P, Pantaleo G,
- 454 Perreau M, Rauch A (Chairman of the Scientific Board), Rudin C, Scherrer AU (Head of Data
- 455 Centre), Schmid P, Speck R, Stöckle M (Chairman of the Clinical and Laboratory
- Committee), Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S.

REFERENCES

457

458

459

- 1. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al.
- Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral
- 462 Therapy. Science. 1997 Nov 14;278(5341):1295–300.
- 2. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of
- Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia.
- 465 Science. 1997 Nov 14;278(5341):1291–5.
- 3. Chun T-W, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, et al. Presence of an
- inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl
- 468 Acad Sci. 1997 Nov 25;94(24):13193–7.
- 469 4. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term
- follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4⁺
- 471 T cells. Nat Med. 2003 Jun;9(6):727–8.
- 5. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of
- latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997 May
- 474 8;387(6629):183–8.
- 6. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool
- of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl
- 477 Acad Sci U S A. 1998 Jul 21;95(15):8869–73.

- 7. Smith MZ, Wightman F, Lewin SR. HIV reservoirs and strategies for eradication. Curr HIV/AIDS Rep. 2012 Mar;9(1):5–15.
- 8. Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011
 Sep;1(1):a007096.
- 9. Ruelas DS, Greene WC. An integrated overview of HIV-1 latency. Cell. 2013 Oct 24;155(3):519–29.
- Han Y, Wind-Rotolo M, Yang H-C, Siliciano JD, Siliciano RF. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol. 2007 Feb;5(2):95–106.
- Hodel F, Patxot M, Snäkä T, Ciuffi A. HIV-1 latent reservoir: size matters. Future Virol.
 2016 Dec;11(12):785–94.
- 488 12. Avettand-Fènoël V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A, et al. Total 489 HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications. Clin 490 Microbiol Rev. 2016 Oct;29(4):859–80.
- 491 13. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A 492 quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature. 493 2019;566(7742):120–5.
- 494 14. Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M,
 495 Vandekerckhove L. Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth.
 496 PLoS Pathog. 2016 Mar;12(3):e1005472.
- 497 15. Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, et al. HIV-1 DNA 498 predicts disease progression and post-treatment virological control. eLife. 2014 Sep 499 12;3:e03821.
- 500 16. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Günthard HF, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis. 2008 Feb 1;197(3):411–9.
- 503 17. Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, et al.
 504 Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of
 505 inflammation or activation. PLOS Pathog. 2017 Apr 20;13(4):e1006285.
- 506 18. Zanchetta M, Walker S, Burighel N, Bellanova D, Rampon O, Giaquinto C, et al. Long-507 term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active 508 antiretroviral therapy. J Infect Dis. 2006 Jun 15;193(12):1718–27.
- 509 19. Chun T-W, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis. 2007 Jun 15;195(12):1762–4.
- 512 20. Strain MC, Günthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, et al.
- Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic
- stability predicts lifelong persistence. Proc Natl Acad Sci U S A. 2003 Apr
- 515 15;100(8):4819–24.

- 516 21. Izopet J, Salama G, Pasquier C, Sandres K, Marchou B, Massip P, et al. Decay of HIV-1
- 517 DNA in patients receiving suppressive antiretroviral therapy. J Acquir Immune Defic
- 518 Syndr Hum Retrovirology Off Publ Int Retrovirology Assoc. 1998 Dec 15;19(5):478–
- 519 83.
- 520 22. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the
- latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of
- residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000
- 523 Jan;6(1):82–5.
- 524 23. van Rij RP, van Praag RME, Prins JM, Rientsma R, Jurriaans S, Lange JMA, et al.
- Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-
- 1 infection with a five-drug regimen. Antivir Ther. 2002 Mar;7(1):37–41.
- 527 24. Pires A, Hardy G, Gazzard B, Gotch F, Imami N. Initiation of antiretroviral therapy
- during recent HIV-1 infection results in lower residual viral reservoirs. J Acquir Immune
- 529 Defic Syndr 1999. 2004 Jul 1;36(3):783–90.
- 530 25. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, et al. Effect of
- treatment, during primary infection, on establishment and clearance of cellular reservoirs
- of HIV-1. J Infect Dis. 2005 May 1;191(9):1410–8.
- 533 26. Fischer M, Joos B, Niederöst B, Kaiser P, Hafner R, von Wyl V, et al. Biphasic decay
- kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during
- antiretroviral therapy. Retrovirology. 2008 Nov 26;5:107.
- 536 27. Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, et al. HIV-1 DNA
- decay dynamics in blood during more than a decade of suppressive antiretroviral
- therapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014 Nov;59(9):1312–21.
- 539 28. Bachmann N, Siebenthal C von, Vongrad V, Turk T, Neumann K, Beerenwinkel N, et
- al. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive
- 541 ART. Nat Commun. 2019 Jul 19;10(1):1–11.
- 542 29. International AIDS Society Scientific Working Group on HIV Cure, Deeks SG, Autran
- B, Berkhout B, Benkirane M, Cairns S, et al. Towards an HIV cure: a global scientific
- strategy. Nat Rev Immunol. 2012 20;12(8):607–14.
- 545 30. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-
- genome association study of major determinants for host control of HIV-1. Science.
- 547 2007 Aug 17;317(5840):944–7.
- 548 31. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, et al. Common
- genetic variation and the control of HIV-1 in humans. PLoS Genet. 2009
- 550 Dec;5(12):e1000791.
- 551 32. Pelak K, Goldstein DB, Walley NM, Fellay J, Ge D, Shianna KV, et al. Host
- determinants of HIV-1 control in African Americans. J Infect Dis. 2010 Apr
- 553 15;201(8):1141–9.

- 33. International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker
- PIW, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide
- presentation. Science. 2010 Dec 10;330(6010):1551–7.
- 34. Herbeck JT, Gottlieb GS, Winkler CA, Nelson GW, An P, Maust BS, et al. Multistage
- genomewide association study identifies a locus at 1q41 associated with rate of HIV-1
- disease progression to clinical AIDS. J Infect Dis. 2010 Feb 15;201(4):618–26.
- 35. Le Clerc S, Limou S, Coulonges C, Carpentier W, Dina C, Taing L, et al. Genomewide
- association study of a rapid progression cohort identifies new susceptibility alleles for
- AIDS (ANRS Genomewide Association Study 03). J Infect Dis. 2009 Oct
- 563 15;200(8):1194–201.
- 36. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, Delaneau O, et al.
- Genomewide association study of an AIDS-nonprogression cohort emphasizes the role
- played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis. 2009
- 567 Feb 1;199(3):419–26.
- 568 37. Limou S, Coulonges C, Herbeck JT, van Manen D, An P, Le Clerc S, et al. Multiple-
- cohort genetic association study reveals CXCR6 as a new chemokine receptor involved
- in long-term nonprogression to AIDS. J Infect Dis. 2010 Sep 15;202(6):908–15.
- 571 38. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix M-L, et al. Distinct
- genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection:
- the ANRS Genome Wide Association 01 study. PloS One. 2008;3(12):e3907.
- 39. McLaren PJ, Pulit SL, Gurdasani D, Bartha I, Shea PR, Pomilla C, et al. Evaluating the
- Impact of Functional Genetic Variation on HIV-1 Control. J Infect Dis. 2017
- 576 27;216(9):1063–9.
- 577 40. Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Günthard HF, Telenti A, et
- al. Cohort Profile: The Swiss HIV Cohort Study. Int J Epidemiol. 2010 Oct
- 579 1;39(5):1179–89.
- 580 41. Loh P-R, Danecek P, Palamara PF, Fuchsberger C, Reshef YA, Finucane HK, et al.
- Reference-based phasing using the Haplotype Reference Consortium panel. Nat Genet.
- 582 2016 Nov;48(11):1443–8.
- 583 42. Durbin R. Efficient haplotype matching and storage using the positional Burrows-
- Wheeler transform (PBWT). Bioinformatics. 2014 May 1;30(9):1266–72.
- 585 43. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A
- reference panel of 64,976 haplotypes for genotype imputation. Nat Genet [Internet].
- 587 2016 Aug 22 [cited 2016 Aug 31]; advance online publication. Available from:
- http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.3643.html
- 589 44. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal
- components analysis corrects for stratification in genome-wide association studies. Nat
- 591 Genet. 2006 Aug;38(8):904–9.
- 592 45. The International HapMap 3 Consortium. Integrating common and rare genetic variation
- in diverse human populations. Nature. 2010 Sep;467(7311):52–8.

- 594 46. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
- 595 PLINK: rising to the challenge of larger and richer datasets. GigaScience. 2015 Dec
- 596 1;4(1):1–16.
- 597 47. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A Tool for Genome-wide Complex Trait Analysis. Am J Hum Genet. 2011 Jan 7;88(1):76–82.
- 599 48. Yang J, Zaitlen NA, Goddard ME, Visscher PM, Price AL. Advantages and pitfalls in the application of mixed-model association methods. Nat Genet. 2014 Feb;46(2):100–6.
- 49. Jia X, Han B, Onengut-Gumuscu S, Chen W-M, Concannon PJ, Rich SS, et al. Imputing
- Amino Acid Polymorphisms in Human Leukocyte Antigens. PLOS ONE. 2013 Jun 6;8(6):e64683.
- 50. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A Whole-
- Genome Association Study of Major Determinants for Host Control of HIV-1. Science.
- 606 2007 Aug 17;317(5840):944–7.
- 51. McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, et al.
- Polymorphisms of large effect explain the majority of the host genetic contribution to
- variation of HIV-1 virus load. Proc Natl Acad Sci. 2015 Nov 24;112(47):14658–63.
- 610 52. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler
- 611 transform. Bioinforma Oxf Engl. 2009 Jul 15;25(14):1754–60.
- 612 53. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The
- Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation
- DNA sequencing data. Genome Res. 2010 Sep 1;20(9):1297–303.
- 615 54. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for
- annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs
- in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012
- 618 Jun;6(2):80–92.
- 619 55. Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, et al. Optimal
- unified approach for rare-variant association testing with application to small-sample
- 621 case-control whole-exome sequencing studies. Am J Hum Genet. 2012 Aug
- 622 10;91(2):224–37.
- 623 56. Dilthey AT, Gourraud P-A, Mentzer AJ, Cereb N, Iqbal Z, McVean G. High-Accuracy
- HLA Type Inference from Whole-Genome Sequencing Data Using Population
- Reference Graphs. PLOS Comput Biol. 2016 Oct 28;12(10):e1005151.
- 57. Fan Y, Song Y-Q. PyHLA: tests for the association between HLA alleles and diseases.
- 627 BMC Bioinformatics. 2017 Feb 6;18(1):90.
- 58. Packer JS, Maxwell EK, O'Dushlaine C, Lopez AE, Dewey FE, Chernomorsky R, et al.
- 629 CLAMMS: a scalable algorithm for calling common and rare copy number variants from
- exome sequencing data. Bioinformatics. 2016 Jan 1;32(1):133–5.

- 631 59. Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, et al. ImmPort,
- toward repurposing of open access immunological assay data for translational and
- 633 clinical research. Sci Data. 2018 27;5:180015.
- 634 60. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and
- association genetic mapping studies of complex traits. Bioinformatics. 2003 Jan
- 636 1;19(1):149–50.
- 637 61. Gutierrez-Arcelus M, Teslovich N, Mola AR, Polidoro RB, Nathan A, Kim H, et al.
- Lymphocyte innateness defined by transcriptional states reflects a balance between
- proliferation and effector functions. Nat Commun. 2019 Feb 8;10(1):1–15.
- 640 62. Marees AT, de Kluiver H, Stringer S, Vorspan F, Curis E, Marie-Claire C, et al. A
- tutorial on conducting genome-wide association studies: Quality control and statistical
- analysis. Int J Methods Psychiatr Res. 2018;27(2):e1608.
- 643 63. Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir
- replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic
- 645 Syndr 1999. 2007 Aug 15;45(5):483–93.
- 646 64. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, et al.
- Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations
- in lymphatic tissues. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2307–12.
- 649 65. Lorenzo-Redondo R, Fryer HR, Bedford T, Kim E-Y, Archer J, Pond SLK, et al.
- Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016
- 651 Feb 4;530(7588):51–6.
- 652 66. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to
- antiretroviral therapy observed prior to transient human immunodeficiency virus type 1
- viremia. J Infect Dis. 2007 Dec 15;196(12):1773–8.
- 655 67. Young J, Rickenbach M, Calmy A, Bernasconi E, Staehelin C, Schmid P, et al. Transient
- detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort
- 657 Study. BMC Infect Dis. 2015 Sep 21;15:382.
- 658 68. Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, et al. Clonally
- expanded CD4+ T cells can produce infectious HIV-1 in vivo. Proc Natl Acad Sci U S
- 660 A. 2016 Feb 16;113(7):1883–8.
- 661 69. Wang Z, Gurule EE, Brennan TP, Gerold JM, Kwon KJ, Hosmane NN, et al. Expanded
- cellular clones carrying replication-competent HIV-1 persist, wax, and wane. Proc Natl
- 663 Acad Sci U S A. 2018 13;115(11):E2575–84.
- 664 70. Lee GQ, Orlova-Fink N, Einkauf K, Chowdhury FZ, Sun X, Harrington S, et al. Clonal
- expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. J Clin
- 666 Invest. 2017 Jun 30;127(7):2689–96.
- 71. Nardacci R, Amendola A, Ciccosanti F, Corazzari M, Esposito V, Vlassi C, et al.
- Autophagy plays an important role in the containment of HIV-1 in nonprogressor-
- infected patients. Autophagy. 2014 Jul;10(7):1167–78.

72. Gaebler C, Lorenzi JCC, Oliveira TY, Nogueira L, Ramos V, Lu C-L, et al. Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. J Exp Med. 2019 Oct 7;216(10):2253-64. 73. Braun DL, Kouyos R, Oberle C, Grube C, Joos B, Fellay J, et al. A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression. PloS One. 2014;9(12):e114111. FIGURE LEGENDS Figure 1. Patient selection flowchart. Specific inclusion and exclusion criteria are listed for each selection step. ART (antiretroviral therapy); PBMCs (peripheral blood mononuclear cells); PI (protease inhibitor); PCA (principal component analysis). Figure 2. Association results with HIV-1 reservoir size. Manhattan plot with association pvalues (-log₁₀(P)) per genetic variant plotted by genomic position. Dashed line indicates the threshold for genome-wide significance (P = 5e-8). No variants were found to be genome-wide significant.

TABLES

Table 1. Patient characteristics	
Total number of individuals	
Genotyped	797
Genotyped + exome sequenced	194
Age at first HIV-1 DNA sample in years	
median (IQR)	44 (38, 50)
Sex	
Female	123 (15.4%)
Male	674 (84.6%)
Transmission group	
HET	241 (30.2%)
IDU	77 (9.7%)
MSM	448 (56.2%)
Other	31 (3.9%)
HIV-1 subtype	
В	550 (69.0%)
Non-B	128 (16.1%)
Unknown	119 (14.9%)
Occurrence of blips or low-level viremia	
Blips	200 (25.1%)
Low-level viremia	68 (8.5%)
None	529 (66.4%)
Time on ART	
median (IQR)	1.50 (1.28, 1.69)
Infection stage	
Acute	140 (17.6%)
Chronic	657 (82.4%)
Time to viral suppression	
median (IQR)	0.34 (0.23, 0.51)
Log ₁₀ HIV-1 plasma RNA pre-ART per mL	
median (IQR)	480 (248, 684)
CD4+ cell count pre-ART cells/µL blood	
median (IQR)	186 (90, 270)
HIV-1 reservoir size	
median (IQR)	2.76 (2.48, 3.03)
HIV-1 reservoir decay rate	
median (IQR)	-0.06 (-0.12, -0.00)

Transmission group indicates the self-reported route of infection (heterosexual (HET), intravenous drug usage (IDU), men who have sex with men (MSM), and other (including transfusions and unknown)). The occurrence of viral blips was defined by measurements of ≥

50 HIV-1 RNA copies/mL plasma within a 30-day window. Individuals with consecutive measurements of \geq 50 HIV-1 RNA copies/mL plasma for longer durations were classified as exhibiting low-level viremia. Time to viral suppression was the time from initiation of ART to the first viral load measurement below 50 copies/mL HIV-1 plasma RNA. HIV-1 reservoir size was measured in \log_{10} total HIV-1 DNA/1 million genomic equivalents \sim 1.5 years after initiating ART. The HIV-1 reservoir decay rate was based on the three measurements of total HIV-1 DNA levels taken at the median of 1.5, 3.5 and 5.4 years after initiation of ART.

18,688 individuals (Swiss HIV Cohort Study, 19/12/2014)

Inclusion criteria:

- HIV-1 infection
 Receiving ART for ≥ 5 years
 No treatment interruption of > 7 days
 No virological failure defined as two consecutive measurements > 200 HIV-1 RNA copies/ml plasma
- PBMCs available for three time points: 1.5 +/- 0.5 years, 3.5 +/- 0.5 years, and 5.5 +/- 1 year, after initiating first-line ART

1932 individuals

Exclusion criteria:

Start on less potent ART regimens, i.e., mono/ or dual therapy, less potent/unboosted PI (NFV, SQV etc.)

1382 individuals

Received ≥ 3 PBMC samples (mandatory 1st - 3rd time point)

1166 individuals

• Successful total HIV-1 DNA quantification in ≥ 3 PBMC samples (mandatory 1st - 3rd time point)

1057 individuals

· Successfully genotyped

995 individuals

• European ancestry (by PCA)

797 individuals 194 individuals + Exome sequencing



